The ability of QT Imaging’s QTscan, a quantitative transmission ultrasound modality, to calculate the ratio of fibroglandular volume to total breast volume may facilitate assessment of ongoing breast cancer treatments or selective hormone receptor modulation therapies.
The Food and Drug Administration (FDA) has granted 510(k) clearance to QT Imaging’s ultrasound-based device QTscan for fibroglandular volume calculations that can help clinicians assess the effectiveness of non-surgical breast cancer treatment.
In addition to aiding in the assessment of breast cancer risk, QT Imaging said the ability of QTscan to calculate the ratio of fibroglandular volume to total breast volume enables radiologists to gauge the progress of non-surgical therapies for patients undergoing treatment for breast cancer. One can also utilize the fibroglandular volume ratio to monitor the use of selective hormone receptor modulation treatment, according to the company.
QT Imaging emphasized that the QTscan is the first ultrasound-based modality to receive FDA clearance for the quantification of fibroglandular volume.
Elaine Iuanow, M.D., a breast imaging specialist, said the calculation of fibroglandular volume with QTscan is an “exciting” advance for the imaging and treatment of breast care patients.
“The ability to determine a therapeutic clinical response using a quantitative volumetric method is crucial for effective and timely treatment of breast cancer and for patients at high risk for developing breast cancer who are receiving hormonal therapy,” noted Dr. Iuanow, a consultant for QT Imaging.
Offering a combination of transmission ultrasound and reflection ultrasound, the QTscan provides “highly accurate” 3D imaging of breast tissue, according to QT Imaging. The company maintained the lack of radiation or compression with the QTscan device allows for more frequent monitoring of adjuvant chemotherapy or radiation therapy in the treatment of breast cancer.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
New Literature Review Finds ChatGPT Effective in Radiology in 84 Percent of Studies
April 29th 2024While noting a variety of pitfalls with the chatbot ranging from hallucinations to improper citations, the review authors found the use of ChatGPT in radiology demonstrated “high performance” in 37 out of 44 studies.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.